MASI Stock - Masimo Corporation
Unlock GoAI Insights for MASI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.09B | $2.05B | $2.04B | $1.24B | $1.14B |
| Gross Profit | $1.00B | $1.00B | $1.06B | $808.40M | $743.00M |
| Gross Margin | 48.0% | 49.0% | 52.0% | 65.2% | 65.0% |
| Operating Income | $-266,700,000 | $136.50M | $210.00M | $275.80M | $255.80M |
| Net Income | $-304,900,000 | $81.50M | $143.50M | $229.60M | $240.30M |
| Net Margin | -14.6% | 4.0% | 7.0% | 18.5% | 21.0% |
| EPS | $-5.72 | $1.54 | $2.68 | $4.16 | $4.39 |
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 17th 2025 | BofA Securities | Initiation | Neutral | - |
| December 27th 2024 | Raymond James | Reiterated | Outperform | $194← $170 |
| November 6th 2024 | Raymond James | Upgrade | Outperform | $170 |
| June 3rd 2024 | Piper Sandler | Upgrade | Overweight | $160← $126 |
| April 15th 2024 | Stifel | Upgrade | Buy | $170← $148 |
| March 25th 2024 | Wells Fargo | Upgrade | Overweight | $160← $117 |
| January 30th 2024 | Jefferies | Downgrade | Hold | $121← $107 |
| January 3rd 2024 | Needham | Downgrade | Hold | - |
| November 8th 2023 | Raymond James | Downgrade | Market Perform | - |
| July 18th 2023 | Stifel | Downgrade | Hold | $120← $205 |
| July 10th 2023 | Wells Fargo | Initiation | Equal Weight | $173 |
| February 22nd 2023 | Raymond James | Upgrade | Outperform | $187 |
| December 15th 2022 | BTIG Research | Upgrade | Buy | $180 |
| December 5th 2022 | Needham | Reiterated | Buy | $173← $149 |
| October 12th 2022 | Jefferies | Initiation | Buy | $180 |
Earnings History & Surprises
MASIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | $1.39 | — | — | — |
Q4 2025 | Nov 4, 2025 | $1.19 | $1.32 | +10.9% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $1.23 | $1.33 | +8.1% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $1.24 | $1.36 | +9.7% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $1.42 | $1.80 | +26.8% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $0.84 | $0.98 | +17.1% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.77 | $0.86 | +11.7% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $0.71 | $0.77 | +8.5% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.95 | $1.25 | +31.6% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $0.59 | $0.63 | +6.8% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.86 | $0.62 | -27.9% | ✗ MISS |
Q2 2023 | May 9, 2023 | $0.83 | $0.87 | +4.8% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $1.17 | $1.32 | +12.8% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.92 | $1.00 | +8.7% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $1.19 | $1.35 | +13.4% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $0.87 | $0.93 | +6.9% | ✓ BEAT |
Q1 2022 | Feb 15, 2022 | $1.10 | $1.21 | +10.0% | ✓ BEAT |
Q4 2021 | Oct 26, 2021 | $0.91 | $0.94 | +3.3% | ✓ BEAT |
Q3 2021 | Jul 27, 2021 | $0.90 | $0.94 | +4.4% | ✓ BEAT |
Q2 2021 | Apr 26, 2021 | $0.88 | $0.90 | +2.3% | ✓ BEAT |
Latest News
BTIG Maintains Buy on Masimo, Raises Price Target to $200
📈 PositiveMasimo Sets 2028 Financial Targets, Sees 7%-10% Revenue CAGR, ~30% Operating Margin, $8 EPS, And $1B Cash Flow; Reaffirms 2025 Guidance Of $1.51B-$1.53B Revenue, $412M-$424M Operating Profit, And $5.40-$5.55 EPS
📈 PositiveMasimo Reiterates 2025 Adjusted EPS Outlook Of $5.40 - $5.55, Expects Adjusted EPS Of $8 By 2028
📈 PositiveBTIG Reiterates Buy on Masimo, Maintains $198 Price Target
📈 PositiveB of A Securities Initiates Coverage On Masimo with Neutral Rating, Announces Price Target of $162
➖ NeutralReported Friday, Masimo Announces $634M Jury Verdict In Patent Case Against Apple Confirming Patent Validity
📈 PositiveWells Fargo Maintains Overweight on Masimo, Lowers Price Target to $187
➖ NeutralBTIG Reiterates Buy on Masimo, Maintains $198 Price Target
📈 PositiveMasimo Raises FY2025 Adj EPS Guidance from $5.45-$5.70 to $5.62-$5.79 vs $5.33 Est; Narrows FY2025 Sales Guidance from $1.505B-$1.535B to $1.510B-$1.530B vs $1.521B Est
📈 PositiveMasimo Q3 Adj. EPS $1.32 Beats $1.20 Estimate, Sales $371.200M Beat $366.848M Estimate
📈 PositiveMasimo Highlights Real-World Trial Data For Masimo SET
➖ NeutralBTIG Reiterates Buy on Masimo, Maintains $198 Price Target
📈 PositivePhilips And Masimo Partner To Advance Access To Patient Monitoring Measurement Technologies
📈 PositiveMasimo Announces FDA 510(k) Clearance Of Expanded Indications For Delta Hemoglobin Parameters Provided With O3 Regional Oximetry
📈 PositiveMasimo to sell its consumer audio business to HARMAN International
➖ NeutralFrequently Asked Questions about MASI
What is MASI's current stock price?
What is the analyst price target for MASI?
What sector is Masimo Corporation in?
What is MASI's market cap?
Does MASI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MASI for comparison